A citation-based method for searching scientific literature

Mijin Kim, Bo Hyun Kim. Endocrinol Metab (Seoul) 2021
Times Cited: 4







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Simon S Terzyan, Tao Shen, Xuan Liu, Qingling Huang, Peng Teng, Mi Zhou, Frank Hilberg, Jianfeng Cai, Blaine H M Mooers, Jie Wu. J Biol Chem 2019
21
50

hERG K(+) channels: structure, function, and clinical significance.
Jamie I Vandenberg, Matthew D Perry, Mark J Perrin, Stefan A Mann, Ying Ke, Adam P Hill. Physiol Rev 2012
402
25

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
658
25

Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Takaaki Oba, Tatsunori Chino, Ai Soma, Tadafumi Shimizu, Mayu Ono, Tokiko Ito, Toshiharu Kanai, Kazuma Maeno, Ken-Ichi Ito. Endocr J 2020
6
25

Ginsenosides for the treatment of metabolic syndrome and cardiovascular diseases: Pharmacology and mechanisms.
Wenxiang Fan, Yongliang Huang, Hui Zheng, Shuiqin Li, Zhuohong Li, Li Yuan, Xi Cheng, Chengshi He, Jianfeng Sun. Biomed Pharmacother 2020
23
25

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Martin Schlumberger, Barbara Jarzab, Maria E Cabanillas, Bruce Robinson, Furio Pacini, Douglas W Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G Martins,[...]. Clin Cancer Res 2016
134
25

Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents Atherosclerosis in ApoE-/- Mice by Regulating PPARγ/FAK Signaling Pathway.
Jianan Geng, Wenwen Fu, Xiaofeng Yu, Zeyuan Lu, Yanzhe Liu, Mingyang Sun, Ping Yu, Xin Li, Li Fu, Huali Xu,[...]. Front Pharmacol 2020
8
25


Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Poupak Fallahi, Silvia Martina Ferrari, Maria Rosaria Galdiero, Gilda Varricchi, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Salvatore Benvenga, Alessandro Antonelli. Semin Cancer Biol 2022
22
25


A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.
M E Curran, I Splawski, K W Timothy, G M Vincent, E D Green, M T Keating. Cell 1995
25

Computational determination of hERG-related cardiotoxicity of drug candidates.
Hyang-Mi Lee, Myeong-Sang Yu, Sayada Reemsha Kazmi, Seong Yun Oh, Ki-Hyeong Rhee, Myung-Ae Bae, Byung Ho Lee, Dae-Seop Shin, Kwang-Seok Oh, Hyithaek Ceong,[...]. BMC Bioinformatics 2019
30
25

Thyroid cancer: pathogenesis and targeted therapy.
David A Liebner, Manisha H Shah. Ther Adv Endocrinol Metab 2011
44
25

Pivotal Roles of Ginsenoside Rg3 in Tumor Apoptosis Through Regulation of Reactive Oxygen Species.
Hwa Yeon Sun, Jun Hee Lee, Yong-Seok Han, Yeo Min Yoon, Chul Won Yun, Jae Heon Kim, Yun Seob Song, Sang Hun Lee. Anticancer Res 2016
21
25



Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.
E N Klein Hesselink, D Steenvoorden, E Kapiteijn, E P Corssmit, A N A van der Horst-Schrivers, J D Lefrandt, T P Links, O M Dekkers. Eur J Endocrinol 2015
44
25

Ginsenoside Rb1 improves cardiac function and remodeling in heart failure.
Xian Zheng, Shuai Wang, Xiaoming Zou, Yating Jing, Ronglai Yang, Siqi Li, Fengrong Wang. Exp Anim 2017
42
25

Ginsenoside Rg3 inhibits colorectal tumor growth via down-regulation of C/EBPβ/NF-κB signaling.
Xiaolai Yang, Jian Zou, Hongyi Cai, Xiaoling Huang, Xiongfei Yang, Dexi Guo, Yongxiao Cao. Biomed Pharmacother 2017
23
25

hERG channel function: beyond long QT.
Joseph J Babcock, Min Li. Acta Pharmacol Sin 2013
48
25

Vandetanib: An overview of its clinical development in NSCLC and other tumors.
A Morabito, M C Piccirillo, R Costanzo, C Sandomenico, G Carillio, G Daniele, P Giordano, J Bryce, P Carotenuto, A La Rocca,[...]. Drugs Today (Barc) 2010
27
25

hERG toxicity assessment: Useful guidelines for drug design.
Amanda Garrido, Alban Lepailleur, Serge M Mignani, Patrick Dallemagne, Christophe Rochais. Eur J Med Chem 2020
25
25

Vandetanib for the treatment of medullary thyroid carcinoma.
Maryann R Cooper, Soo Yun Yi, Wael Alghamdi, Daniel J Shaheen, Michael Steinberg. Ann Pharmacother 2014
13
25

Increase in CO2 levels by upregulating late sodium current is proarrhythmic in the heart.
Qing Zhang, Ji-Hua Ma, Hong Li, Xiao-Hong Wei, Jie Zheng, Gang Li, Cheng-Yu Wang, Ying Wu, Qi-Hua He, Lin Wu. Heart Rhythm 2019
5
25

Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.
Matteo Santoni, Federico Guerra, Alessandro Conti, Alessandra Lucarelli, Silvia Rinaldi, Laura Belvederesi, Alessandro Capucci, Rossana Berardi. Cancer Treat Rev 2017
33
25

hERG 1b is critical for human cardiac repolarization.
David K Jones, Fang Liu, Ravi Vaidyanathan, L Lee Eckhardt, Matthew C Trudeau, Gail A Robertson. Proc Natl Acad Sci U S A 2014
56
25

Selective use of vandetanib in the treatment of thyroid cancer.
Poupak Fallahi, Flavia Di Bari, Silvia Martina Ferrari, Roberto Spisni, Gabriele Materazzi, Paolo Miccoli, Salvatore Benvenga, Alessandro Antonelli. Drug Des Devel Ther 2015
22
25

Anticancer effects of ginsenoside Rg3 (Review).
Mengyao Sun, Ying Ye, Ling Xiao, Xinya Duan, Yongming Zhang, Hong Zhang. Int J Mol Med 2017
104
25

Fetal cardiac repolarization abnormalities.
Hui Zhao, Janette F Strasburger, Bettina F Cuneo, Ronald T Wakai. Am J Cardiol 2006
36
25

Mechanisms of drug induced QT interval prolongation.
Marcelo Luis Ponte, Guillermo Alberto Keller, Guillermo Di Girolamo. Curr Drug Saf 2010
48
25


Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis.
Jiajie Zang, Shunquan Wu, Lei Tang, Xudong Xu, Jie Bai, Caicui Ding, Yue Chang, Long Yue, Enming Kang, Jia He. PLoS One 2012
53
25

The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Jules C Hancox, Mark J McPate, Aziza El Harchi, Yi Hong Zhang. Pharmacol Ther 2008
196
25

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer.
Hari Deshpande, Sanziana Roman, Jaykumar Thumar, Julie Ann Sosa. Clin Med Insights Oncol 2011
25
25

Ginsenoside Rg(3) decelerates hERG K(+) channel deactivation through Ser631 residue interaction.
Sun-Hye Choi, Tae-Joon Shin, Sung-Hee Hwang, Byung-Hwan Lee, Jiyeon Kang, Hyeon-Joong Kim, Su-Hyun Jo, Han Choe, Seung-Yeol Nah. Eur J Pharmacol 2011
17
25


c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines.
Yuichiro Ohshima, Ichiro Yajima, Kozue Takeda, Machiko Iida, Mayuko Kumasaka, Yoshinari Matsumoto, Masashi Kato. PLoS One 2010
36
25

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
171
25

A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Takashi Nakaoku, Takashi Kohno, Mitsugu Araki, Seiji Niho, Rakhee Chauhan, Phillip P Knowles, Katsuya Tsuchihara, Shingo Matsumoto, Yoko Shimada, Sachiyo Mimaki,[...]. Nat Commun 2018
52
25


Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations.
Rebecca L Margraf, David K Crockett, Patti M F Krautscheid, Ryan Seamons, Fernanda R O Calderon, Carl T Wittwer, Rong Mao. Hum Mutat 2009
98
25

RET fusions in solid tumors.
Andrew Y Li, Michael G McCusker, Alessandro Russo, Katherine A Scilla, Allison Gittens, Katherine Arensmeyer, Ranee Mehra, Vincenzo Adamo, Christian Rolfo. Cancer Treat Rev 2019
76
25

RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
Takuo Hayashi, Igor Odintsov, Roger S Smith, Kota Ishizawa, Allan J W Liu, Lukas Delasos, Christopher Kurzatkowski, Huichun Tai, Eric Gladstone, Morana Vojnic,[...]. Dis Model Mech 2020
6
25

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.
Gang G Li, Romel Somwar, James Joseph, Roger S Smith, Takuo Hayashi, Leenus Martin, Aleksandra Franovic, Anni Schairer, Eric Martin, Gregory J Riely,[...]. Clin Cancer Res 2017
50
25


Catalog of 5' fusion partners in RET+ NSCLC Circa 2020.
Sai-Hong Ignatius Ou, Viola W Zhu. JTO Clin Res Rep 2020
5
25

KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space.
Oscar P J van Linden, Albert J Kooistra, Rob Leurs, Iwan J P de Esch, Chris de Graaf. J Med Chem 2014
165
25

Pralsetinib: First Approval.
Anthony Markham. Drugs 2020
31
25

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature.
Sara Baglivo, Vienna Ludovini, Riccardo Moretti, Guido Bellezza, Angelo Sidoni, Fausto Roila, Giulio Metro. Oncol Ther 2020
10
25

Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
Ly Nguyen, Shanada Monestime. Am J Health Syst Pharm 2022
1
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.